Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

New Agreement

20 Jan 2005 07:01

Angle PLC20 January 2005 For Immediate Release 20 January 2005 ANGLE plc ANGLE signs Agreement with Ben Franklin Technology Partners to advance the growth of Technology Companies in Pennsylvania ANGLE plc, a leading international venture management and consulting companyfocusing on technology commercialisation today announced that it has signed aMemorandum of Understanding (MOU) with Ben Franklin Technology Partners ofSoutheastern Pennsylvania (BFTP/SEP), an internationally recognised economicdevelopment organisation, to advance the growth of technology-based companies inthe Greater Philadelphia region. Under the terms of the MOU, it is contemplated that ANGLE will commit no lessthan $5 million over five years for funding new technology spin-outs that meetits Progeny(R) requirements. This funding will be matched by BFTP/SEP - thusdoubling the leverage on ANGLE funds for creating ventures and similarlyleveraging BFTP/SEP's economic development funds. The Greater Philadelphia region is home to many of the world's most renownedacademic institutions including the University of Pennsylvania - one of theleading research universities in the United States. Collectively, the region'sacademic institutions attract more than $1 billion of research funding perannum, generating more than 200 patent applications per year. The region iswell recognised as a global leader in the bio-pharma and medical research arena. As part of the MOU, ANGLE will serve as BFTP/SEP's preferred commercialisationpartner for technologies from universities, colleges and related institutions inthe region, and become a corporate member of the Nanotechnology Institute, aninternationally recognised alliance of business, academia and government that isfacilitating the research and development and commercialisation of bio/nanoadvances. Commenting on the joint venture, Dr. Gary Evans, CEO of ANGLE's U.S. businessoperations said, "Our MOU and partnership with BFTP/SEP provides a uniqueopportunity both to extend our base of operation in the U.S. Mid-Atlantic regionand to complement an already robust technology commercialisation community. Inaddition to its formidable research capabilities, and its pre-eminentpharmaceutical industry, the region is highly regarded for developing newcutting edge research-to-commercialisation models around nanotechnology and bio/nanotechnology." "The ANGLE MOU is indicative of the synergy that occurs when distinct entitiesshare a common goal. It addresses critical management and capital needs at theearliest points in the commercialisation of new discoveries - just pasttranslational research to pre-seed, including pre-proof of concept,pre-prototype, pre-science/management team, pre-company formation. Liketechnology, this cross-Atlantic partnership has the potential to have asignificant global impact," said RoseAnn B. Rosenthal, president and CEO of BFTP/SEP. Andrew Newland, Chief Executive of ANGLE plc said, "This is a major developmentof our Ventures business in the U.S. It demonstrates the success of ourbusiness model and the leverage we generate between our Consulting and Venturesbusinesses. Our relationship with BFTP/SEP has developed from successfulconsulting work in Pennsylvania for Ben Franklin and others, including thedevelopment of the strategy for nanotechnology in the Commonwealth ofPennsylvania. We look forward to developing world-class ventures as a result ofthis expanded partnership." Notes to Editors: Founded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. ANGLE plc floated on the Alternative Investment Market of the London StockExchange on 17 March 2004. About Ben Franklin Technology Partners of Southeastern Pennsylvania Since 1982, Ben Franklin Technology Partners of Southeastern Pennsylvania (BFTP/SEP) has helped grow the region through science, technology andentrepreneurship. BFTP/SEP provides entrepreneurs and established businesses thecapital, talent, and expertise they need to compete in the global marketplace.Like its namesake, Ben Franklin invests in, builds upon and delivers solutionsthat grow communities and create wealth by supporting today's technologicalideas and tomorrow's scientific discovery. For further information: ANGLE plc 01483 295830Andrew Newland, Chief ExecutiveDawson Buck, Deputy Chief Executive Buchanan Communications 020 7466 5000Richard Darby, Suzanne Brocks This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
28th Jul 20227:00 amRNSNovel insight into metastasis in NSCLC patients
20th Jul 20222:33 pmRNSHolding(s) in Company
20th Jul 20227:00 amRNSNEW STUDY OF PARSORTIX SYSTEM IN NSCLC
19th Jul 202210:00 amRNSDirector/PDMR Shareholding
15th Jul 20227:00 amRNSResults of Capital Raise
14th Jul 20225:24 pmRNSRetail Offer via PrimaryBid
14th Jul 20225:23 pmRNSProposed Placing and Retail Offer
8th Jul 20225:30 pmRNSIssue of Equity
29th Jun 20224:35 pmRNSResult of 2022 Annual General Meeting
27th Jun 20227:00 amRNSSpread of breast cancer accelerates during sleep
23rd Jun 20226:24 pmRNSIssue of Equity
22nd Jun 20227:00 amRNSSecured contract from pharma services customer
16th Jun 20227:00 amRNSPredicting immunotherapy response in SCLC
14th Jun 20227:00 amRNSPotential role of invasive cellular protrusions
30th May 20227:00 amRNSPartnership with major United States urology group
27th May 20227:00 amRNSMolecular characterisation of CTCs
25th May 20224:35 pmRNSPrice Monitoring Extension
25th May 202212:30 pmRNSANGLE receives FDA clearance for Parsortix
20th May 20227:00 amRNSProstate Cancer UK funds new study using Parsortix
28th Apr 20227:00 amRNSPreliminary Results
20th Apr 20227:00 amRNSNotice of Preliminary Results and Webcast
14th Apr 20227:00 amRNSPoster on Parsortix system presented at AACR 2022
1st Apr 20227:00 amRNSIdentifying drug targets in cancer metastasis
29th Mar 20227:00 amRNSRapid information on patient response to therapies
25th Mar 20227:00 amRNSIdentifying therapeutic targets in TNBC patients
15th Mar 20227:00 amRNSUpdate on laboratory accreditation
9th Mar 20224:41 pmRNSSecond Price Monitoring Extn
9th Mar 20224:36 pmRNSPrice Monitoring Extension
2nd Mar 20226:29 pmRNSHolding(s) in Company
18th Feb 20225:13 pmRNSIssue of Equity
21st Jan 20227:00 amRNSPotential in immunotherapy treatment selection
17th Jan 20227:00 amRNSConcordance of Parsortix with tissue biopsy
13th Jan 20227:00 amRNSUpdate on lab accreditation and ovarian study
10th Jan 20227:00 amRNSInsight into drug resistance in NSCLC
22nd Dec 20216:29 pmRNSIssue of Equity
1st Dec 20216:11 pmRNSIssue of Equity
1st Dec 20217:00 amRNSParsortix in RNA analysis of CTCs as tool in NSCLC
26th Nov 20215:33 pmRNSIssue of Equity
17th Nov 202110:32 amRNSIssue of Equity
15th Nov 20217:00 amRNSIssue of LTIP Options and Share Options
15th Nov 20217:00 amRNSAppointment of Chief Medical Officer
12th Nov 20215:51 pmRNSIssue of Equity
12th Nov 20217:00 amRNSParticipation at Jefferies healthcare conference
11th Nov 20217:00 amRNSParsortix system showcased at NCRI Festival
10th Nov 20215:40 pmRNSIssue of Equity
2nd Nov 20217:00 amRNSChange of Adviser
21st Oct 20215:25 pmRNSIssue of Equity
15th Oct 20215:45 pmRNSIssue of Equity
30th Sep 20214:02 pmRNSIssue of Equity
30th Sep 20217:00 amRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.